Literature DB >> 19828412

Loco-regional control after postoperative radiotherapy for patients with regional nodal metastases from melanoma.

Carlos Conill1, Izaskun Valduvieco, Josep Domingo-Domènech, Pedro Arguis, Sergi Vidal-Sicart, Antonio Vilalta.   

Abstract

INTRODUCTION: The role of adjuvant radiation therapy (RT) following nodal surgery in malignant melanoma remains controversial. There are no published randomised trials comparing surgery alone to surgery with postoperative RT. AIM AND METHODS: The purpose of the present retrospective study was to review the results of loco-regional control after postoperative RT in patients with nodal metastases of melanoma. Seventy-seven patients with high-risk disease (lymph nodes > or =3 cm, more than three lymph nodes involved, extracapsular extension and recurrent disease) were treated with adjuvant RT. Hypofractionation was used in 65 patients and conventional fractionation in 12 patients.
RESULTS: Seventy-seven patients with nodal metastases from melanoma were managed with lymphadenectomy and radiation, with or without systemic therapy. The median age was 56 years old (range: 21-83). There were 47 males (61%) and 30 females (39%). Loco-regional control was observed in 95% of patients (73/77). The actuarial 5-year in-field loco-regional control rate was 90% (mean: 105 months; CI95%: 96-115 months). Median metastasis disease- free survival (MDFS) was 16 months (CI95%: 13-18 months). Median survival time (MST) for the entire group was 26 months (CI95%: 18-34 months). MST according to the localisation of node metastases (groin, axilla and cervical) was also analysed, without statistically significant differences (p=0.08). Concerning the number of risk factors score, analysis of survival did not show statistically significant differences (p=0.055).
CONCLUSIONS: Despite the high incidence of distant metastases, loco-regional control remains an important goal in the management of melanoma. Surgery and adjuvant RT provides excellent loco-regional control, although distant metastases remain the major cause of mortality.

Entities:  

Mesh:

Year:  2009        PMID: 19828412     DOI: 10.1007/s12094-009-0425-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  34 in total

1.  Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation.

Authors:  Daniel T Chang; Robert J Amdur; Christopher G Morris; William M Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-12       Impact factor: 7.038

2.  NCCN melanoma practice guidelines. National Comprehensive Cancer Network.

Authors:  A Houghton; D Coit; W Bloomer; A Buzaid; D Chu; B Eisenburgh; J Guitart; T Johnson; S Miller; S Sener; K Tanabe; J Thompson; M Urist; M Walker
Journal:  Oncology (Williston Park)       Date:  1998-07       Impact factor: 2.990

3.  Sentinel lymph node biopsy in malignant melanoma: the standard of care?

Authors:  J C Emilia; W Lawrence
Journal:  J Surg Oncol       Date:  1997-07       Impact factor: 3.454

4.  Adjuvant irradiation for axillary metastases from malignant melanoma.

Authors:  Matthew T Ballo; Eric A Strom; Gunar K Zagars; Agop Y Bedikian; Victor G Prieto; Paul F Mansfield; Jeffrey E Lee; Jeffrey E Gershenwald; Merrick I Ross
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-03-15       Impact factor: 7.038

5.  Concurrent adjuvant radiotherapy and interferon-alpha2b for resected high risk stage III melanoma -- a retrospective single centre study.

Authors:  David E Gyorki; Jill Ainslie; Michael Lim Joon; Michael A Henderson; Michael Millward; Grant A McArthur
Journal:  Melanoma Res       Date:  2004-06       Impact factor: 3.599

6.  Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients.

Authors:  Carlos Conill; Sandra Jorcano; Josep Domingo-Domènech; Jordi Marruecos; Ramón Vilella; Josep Malvehy; Susana Puig; Marcelo Sánchez; Rosa Gallego; Teresa Castel
Journal:  Melanoma Res       Date:  2007-10       Impact factor: 3.599

7.  Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck.

Authors:  Mark D Bonnen; Matthew T Ballo; Jeffrey N Myers; Adam S Garden; Eduardo M Diaz; Jeffrey E Gershenwald; William H Morrison; Jeffrey E Lee; Mary Jane Oswald; Merrick I Ross; K Kian Ang
Journal:  Cancer       Date:  2004-01-15       Impact factor: 6.860

8.  Concurrent interferon-alpha and radiation for head and neck melanoma.

Authors:  N P Nguyen; B Levinson; S Dutta; U Karlsson; A Alfieri; C Childress; S Sallah
Journal:  Melanoma Res       Date:  2003-02       Impact factor: 3.599

9.  Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma.

Authors:  Beth M Beadle; B Ashleigh Guadagnolo; Matthew T Ballo; Jeffrey E Lee; Jeffrey E Gershenwald; Janice N Cormier; Paul F Mansfield; Merrick I Ross; Gunar K Zagars
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-09-05       Impact factor: 7.038

10.  Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control.

Authors:  E A Strom; M I Ross
Journal:  Ann Surg Oncol       Date:  1995-09       Impact factor: 5.344

View more
  1 in total

1.  Percutaneous Cryoablation for Local Control of Metachronous Inguinal Lymph Node Metastases.

Authors:  Francois Cornelis; Philip B Paty; Constantinos T Sofocleous; Stephen B Solomon; Jeremy C Durack
Journal:  Cardiovasc Intervent Radiol       Date:  2014-07-01       Impact factor: 2.740

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.